Amarin Corp Plc (AMRN)

[garynavarre]

Amarin should split into 2 separately traded companies. The first would include USA, Canada, China and any other areas from which they will receive only royalty payments. The second company will hold the rights to market Vascepa in the EU and ROW. Under this configuration, the USA company can continue the patent fight for as long as it takes and big pharma can buy the second company without the headaches of the US including a lengthy patent fight, current GIA infrastructure, etc. If Amarin is eventually successful in the patent fight, they could also sell this to big pharma or continue to GIA.